Page 26 - FBL AR 2019-20

Fermenta Biotech Limited
Annual Report 2019-20

infrastructure audited by demanding making us integral to their growth and
global regulatory agencies; we success.
benchmarked our infrastructure in line At Fermenta, we will grow our
with evolving compliances designed to manufacturing capacity through
exceed regulatory standards; we invested investments that could enhance our
in cutting-edge technologies and state- proximity to customers across the
of-the-art equipment; we extended world, shrink delivery turnarounds and
to adjacent value-added segments by strengthen our global positioning.
bringing in value-added variants.
The addressable headroom is vast in our
At Fermenta, we raised our benchmarks business: new Vitamin D3 applications
in line with the best in the world. We are being developed while the number
generated superior production efficiencies, of players is not increasing as the industry
shrank our learning curve, sweated assets continues to be protected by a high
better, enhanced product purity and technology entry barrier. Dietary sources
strengthened operational safety. The result contribute only a small amount of Vitamin
is that we are not only among the largest D in countries like India, marked by a low
Vitamin D providers in the world and fortification of foods. The irony is that
among the most competitive; we are also despite abundant sunlight, a large section
considered among the most dependable of the Indian population (~90%) suffers
when it comes to product, service and from low Vitamin D levels.
safety. The result is reflected in our multi-
decade engagements with customers,

What we were

Product-focused Generating Manufacturing Standalone Asset-driven Capability in
Company revenues largely presence in India operations business pharma and animal
from Vitamin D3 feed applications

24